New targeted therapy trial offers hope for Tough-to-Treat lung cancer
NCT ID NCT06430437
Summary
This study is testing whether an experimental drug called SHR-A1811 works better than current standard treatments for people with advanced lung cancer that has specific HER2 mutations. Researchers will enroll 300 adults who haven't had previous treatment for their advanced cancer, comparing how long patients live without their cancer worsening and monitoring side effects. The goal is to find a more effective treatment option for this specific type of lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH HER2- MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
Conditions
Explore the condition pages connected to this study.